Intravesical NGF Antisense Therapy Using Lipid Nanoparticle for Interstitial Cystitis
Abstract
The Technology/Therapeutic Development Award titled Intravesical NGF antisense therapy using lipid nanoparticle for interstitial cystitis evaluates the feasibility of an anti-nerve growth factor (NGF) bladder drug delivery as a treatment for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS). IC/PBS is a chronic, severely debilitating disease of the urinary bladder which was included as a FY11 Topic Areas of The Peer Reviewed Medical Research Program (PRMRP). The goal of this project is to advance the development of a potential new drug candidate. Specific aims of the project include early stage development, initial manufacture, and animal testing of an experimental liposome NGF-antisense formulations for bladder pain. During the second year of the project, investigators continued development and conducted GMP compliant pilot scale manufacturing product batches, conducted IND relevant study of product formulation and stability, and conducted in-vivo investigation of liposome NGF-antisense formulation in a novel diseased animal model.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2014
- Accession Number
- ADA613991
Entities
People
- David Chancellor
- Michael B Chancellor
- Michele Gruber
- Naoki Yoshimura